Updates are available Correction dated 2025-03-26
Click to view Correction: https://doi.org/10.1186/s13059-025-03548-z
-
Authors
Glaser, Viktor
Flugel, Christian
Kath, Jonas
Du, Weijie
Drosdek, Vanessa
Franke, Clemens
Stein, Maik
Pruß, Axel
Schmueck-Henneresse, Michael
Volk, Hans-Dieter
Reinke, Petra
Wagner, Dimitrios L. https://orcid.org/0000-0002-2189-3579
-
Funding
Funding for this research was provided by:
H2020 Societal Challenges (No 825392)
Berlin Institute of Health (New Crossfield "Genome Engineering", SPARK-BIH)
Charité - Universitätsmedizin Berlin
- License Information
-
More Information
Article History
Received: 21 November 2022
Accepted: 6 April 2023
First Online: 24 April 2023
Change Date: 26 March 2025
Change Type: Correction
Change Details: A Correction to this paper has been published:
Change Details: https://doi.org/10.1186/s13059-025-03548-z
Declarations
:
: The study was performed in accordance with the Declaration of Helsinki. Peripheral blood from healthy human donors was obtained after informed and written consent (Charité ethics committee approval EA4/091/19).
: Charité has received reagents for gene editing (TRAC sgRNA Cas9, custom gblocks) from Integrated DNA technologies Inc as part of a collaboration agreement. H-DV is founder and CSO at CheckImmune GmbH. PR, H-DV, and DLW are co-founders of the startup TCBalance Biopharmaceuticals GmbH focused on regulatory T cell therapy. JK, WD, MS-H, PR, H-DV, and DLW are listed as inventors on patent applications for cell and gene therapies. All other authors declare that they have no competing interests.
